How Much Does Ozempic Cost in North Dakota in 2026?

Brand-Name Ozempic Pricing at North Dakota Pharmacies

A single Ozempic pen at the manufacturer's wholesale acquisition cost (WAC) runs $998 per month across North Dakota retail pharmacies in 2026, matching the national list price set by Novo Nordisk. That figure applies to all dose strengths (0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg) since each pen contains a four-week supply.

Pharmacy-to-pharmacy variation in North Dakota is minimal. The state has roughly 130 licensed retail pharmacies, most of them independent or part of regional chains like Thrifty White. Without insurance or a discount card, expect to pay the full $998 at the register. Some big-box pharmacies in Fargo and Bismarck may list marginally lower cash prices ($935 to $975), but the savings are small relative to the total.

The pricing gap between Ozempic and its sister drug Wegovy (semaglutide 2.4 mg, FDA-approved for chronic weight management) is narrowing. Wegovy lists at $1,349 per month. For North Dakota patients prescribed Ozempic specifically for type 2 diabetes, the cost difference matters when comparing formulary tiers across commercial plans.

Novo Nordisk has not announced a list-price reduction for 2026. The company did state in its Q1 2026 earnings call that net prices (after rebates to pharmacy benefit managers) have declined roughly 40% from WAC over the past three years, but those rebates do not directly lower what an uninsured patient pays at the counter.

North Dakota Medicaid and Ozempic Coverage

North Dakota Medicaid does not cover Ozempic when prescribed off-label for weight management. The state's preferred drug list (PDL), administered by the North Dakota Department of Health and Human Services, includes semaglutide only under the type 2 diabetes category with prior authorization requirements.

For a patient with a confirmed type 2 diabetes diagnosis and an HbA1c of 7.0% or higher, Medicaid may approve Ozempic after documented failure of metformin therapy. The prior authorization form requires the prescriber to confirm the patient has tried at least one first-line oral agent for 90 days. This aligns with American Diabetes Association Standards of Care, which position GLP-1 receptor agonists as second-line agents for patients with established cardiovascular disease or high cardiovascular risk [1].

North Dakota expanded Medicaid under the ACA in 2014. As of 2026, roughly 19,000 adults are enrolled in expansion Medicaid. None of these beneficiaries have a formulary pathway to Ozempic solely for weight loss.

For patients who carry both a type 2 diabetes diagnosis and obesity (BMI ≥30), the clinical documentation should emphasize glycemic control as the primary indication. Prescribers in North Dakota report higher approval rates when the prior authorization narrative includes specific HbA1c values and a timeline of metformin use.

Compounded Semaglutide in North Dakota: Legality, Cost, and Risks

Compounded semaglutide is available in North Dakota through licensed 503A compounding pharmacies at roughly $199 per month. That price point is 80% below brand Ozempic.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications, including semaglutide, based on a valid individual prescription. North Dakota's Board of Pharmacy oversees these pharmacies under NDCC Chapter 43-15. A 503A pharmacy in North Dakota must compound semaglutide in response to a specific patient prescription rather than producing it in bulk.

The FDA issued a warning letter in October 2023 noting that compounded semaglutide products have not undergone FDA review for safety, efficacy, or quality. Reports of adverse events tied to compounded GLP-1 receptor agonists include dosing errors, contamination, and the use of semaglutide sodium salt (a different molecular form than the base used in Ozempic) [2].

Patients considering compounded semaglutide in North Dakota should verify three things: the pharmacy holds a valid ND Board of Pharmacy compounding license, the product uses semaglutide base (not the sodium salt), and the pharmacy can provide a certificate of analysis from a third-party testing lab. The price advantage is real. So is the quality variance.

SUSTAIN-7 (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks, demonstrating superior HbA1c reduction (1.5% vs. 1.1% for the higher doses) and greater weight loss (6.5 kg vs. 3.0 kg) with semaglutide [3]. Those results were generated with pharmaceutical-grade semaglutide manufactured under FDA-inspected cGMP conditions, not compounded formulations.

Insurance Coverage for Ozempic in North Dakota

Commercial insurance coverage for Ozempic in North Dakota varies by plan, employer, and pharmacy benefit manager (PBM). The three largest insurers writing individual and group plans in the state are Blue Cross Blue Shield of North Dakota (BCBSND), Sanford Health Plan, and Medica.

BCBSND covers Ozempic on most employer-sponsored plans with prior authorization for type 2 diabetes. The typical copay for a preferred brand on a three-tier formulary falls between $50 and $150 per month. Sanford Health Plan similarly covers Ozempic as a Tier 3 preferred brand for diabetes, with step therapy requiring prior metformin use.

For federal employees in North Dakota, the Federal Employees Health Benefits (FEHB) program covers Ozempic under most plan options. The Blue Cross Blue Shield Federal Employee Program (FEP) lists semaglutide as a covered specialty drug with a $100 to $250 copay depending on the specific plan tier selected during open enrollment.

Medicare Part D covers Ozempic for type 2 diabetes but does not cover it for weight loss. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect in 2025, Medicare beneficiaries in North Dakota now pay a maximum of $2,000 per year across all covered Part D drugs. For a patient whose only Part D medication is Ozempic, that cap limits annual exposure to $2,000 rather than the $11,976 list price ($998 x 12).

"North Dakota insurers are increasingly requiring step therapy documentation before authorizing GLP-1 receptor agonists," according to the Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity. The guideline recommends GLP-1 RAs as first-line pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities [4].

The Novo Nordisk Savings Card: How It Works in North Dakota

The Novo Nordisk Ozempic Savings Card reduces out-of-pocket costs to as low as $25 per 28-day fill for eligible patients. The card works at every retail pharmacy in North Dakota that accepts commercial insurance.

Eligibility requires commercial or private insurance. Patients on Medicare, Medicaid, Tricare, or any other federal or state government-funded program are excluded. The card covers up to $150 per fill in copay assistance for a maximum of 24 months. If a patient's insurance copay is $175, the card pays $150 and the patient pays $25.

There is no income requirement. Activation takes roughly two minutes through the Novo Nordisk website or by calling 1-877-304-6855. The pharmacist processes it as a secondary payer at the point of sale.

For North Dakota patients without any insurance, Novo Nordisk's Patient Assistance Program (PAP) provides Ozempic at no cost to households earning below 400% of the federal poverty level ($62,400 for a single adult in 2026). The application requires income documentation and a prescriber signature. Approval typically takes 10 to 14 business days [5].

Telehealth Prescribing of Ozempic in North Dakota

North Dakota permits telehealth prescribing of Ozempic without geographic restriction. State law (NDCC 43-17-01) defines telemedicine as a valid modality for establishing a patient-provider relationship, and the North Dakota Board of Medicine does not require an in-person visit before prescribing GLP-1 receptor agonists.

Multiple national telehealth platforms serve North Dakota patients, including HealthRX, Ro, Calibrate, and Found. Prices for telehealth consultations range from $0 (included in the medication cost) to $99 per visit. Some platforms bundle the consultation fee into a monthly subscription that includes the compounded semaglutide supply.

A telehealth prescriber in North Dakota must hold an active North Dakota medical license or practice under the Interstate Medical Licensure Compact, which North Dakota joined in 2017. The Compact allows physicians licensed in any of its 42 member states to obtain expedited North Dakota licensure.

For patients in rural North Dakota counties (where 26 of 53 counties lack an endocrinologist), telehealth removes a significant access barrier. A 2023 JAMA Network Open study found that telehealth GLP-1 prescribing increased 340% between 2020 and 2023, with the highest per-capita growth in rural ZIP codes [6].

Comparing Ozempic Alternatives Available in North Dakota

Ozempic is not the only semaglutide product on the market, and it is not the only GLP-1 receptor agonist available in North Dakota.

| Drug | Active Ingredient | FDA Indication | ND Cash Price (approx.) | |---|---|---|---| | Ozempic | Semaglutide 0.5-2.0 mg | Type 2 diabetes | $998/month | | Wegovy | Semaglutide 2.4 mg | Chronic weight management | $1,349/month | | Mounjaro | Tirzepatide 2.5-15 mg | Type 2 diabetes | $1,023/month | | Zepbound | Tirzepatide 2.5-15 mg | Chronic weight management | $1,059/month | | Rybelsus | Oral semaglutide 7-14 mg | Type 2 diabetes | $935/month | | Compounded semaglutide | Semaglutide (503A) | Per prescriber | ~$199/month |

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial (N=2,539) demonstrated 20.9% mean body weight reduction at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo [7]. For North Dakota patients whose primary goal is weight loss and whose insurance does not cover Ozempic, tirzepatide may offer a clinical advantage at a comparable price point.

Oral semaglutide (Rybelsus) provides a needle-free option. The PIONEER-6 trial (N=3,183) confirmed cardiovascular safety for oral semaglutide, though the 14 mg oral dose produces less weight loss than injectable semaglutide 1.0 mg [8]. Rybelsus costs roughly $935 per month at North Dakota pharmacies without insurance.

How to Get the Lowest Ozempic Price in North Dakota

The lowest-cost path depends on insurance status. Here is a decision framework for North Dakota patients:

Commercially insured with type 2 diabetes: Use the Novo Nordisk savings card alongside your insurance. Expected out-of-pocket: $25 to $50 per month.

Commercially insured, prescribed off-label for weight loss: Check whether your specific plan covers Ozempic for weight management (some self-insured employer plans do). If not, ask your prescriber about Wegovy or Zepbound, which carry FDA weight-loss indications and may have separate formulary coverage.

Medicare Part D with type 2 diabetes: The $2,000 annual cap applies. Expected cost: $167 per month averaged across the year.

Uninsured, income below 400% FPL: Apply for the Novo Nordisk Patient Assistance Program. Expected cost: $0.

Uninsured, income above 400% FPL: Compounded semaglutide from a licensed North Dakota 503A pharmacy at approximately $199 per month represents the lowest available price. Verify pharmacy licensure through the North Dakota Board of Pharmacy before filling.

"For patients with type 2 diabetes and obesity, the cost-effectiveness of GLP-1 receptor agonists improves substantially when cardiovascular risk reduction is factored into the analysis," noted the 2024 ADA Standards of Care [9]. The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg versus placebo in patients with established cardiovascular disease and overweight or obesity without diabetes [10].

North Dakota patients filling Ozempic at Costco or Mark's Family Pharmacy in Bismarck should ask for a cash-price quote in addition to running insurance, since some high-deductible plans produce a lower total cost when the savings card is applied to a cash transaction rather than processed through the PBM.